ESSA Pharma (NASDAQ:EPIX) Earns Outperform Rating from Analysts at Oppenheimer

Investment analysts at Oppenheimer initiated coverage on shares of ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) in a research note issued on Thursday, The Fly reports. The firm set an “outperform” rating and a $8.00 price target on the stock. Oppenheimer’s price objective would indicate a potential upside of 83.07% from the company’s current price.

Separately, ValuEngine cut ESSA Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 19th.

NASDAQ:EPIX traded up $0.02 during trading hours on Thursday, hitting $4.37. The company’s stock had a trading volume of 39,400 shares, compared to its average volume of 18,888. The business’s 50-day moving average is $3.21 and its two-hundred day moving average is $2.56. The company has a market capitalization of $60.27 million, a PE ratio of -1.71 and a beta of 1.90. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.06 and a current ratio of 1.06. ESSA Pharma has a 52-week low of $1.41 and a 52-week high of $4.54.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.02. As a group, analysts predict that ESSA Pharma will post -1.52 EPS for the current fiscal year.

ESSA Pharma Company Profile

ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Read More: Blue-Chip Stocks

The Fly

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.